1. Home
  2. HLVX

as 02-21-2025 12:37pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Founded: 2020 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 92.6M IPO Year: 2022
Target Price: $2.33 AVG Volume (30 days): 180.1K
Analyst Decision: Hold Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.09 EPS Growth: N/A
52 Week Low/High: $1.55 - $20.22 Next Earning Date: 03-19-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

HLVX Daily Stock ML Predictions

Stock Insider Trading Activity of HilleVax Inc. (HLVX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Maltbie Shane HLVX Chief Financial Officer Feb 4 '25 Sell $1.83 8,291 $15,116.87 84,232

Share on Social Networks: